3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
2
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
258
Sarcoma
69
Dermatologic
41
Endocrine
24
Thoracic
23
Gastrointestinal
22
NET
12
Lymphoid
11
Breast
9
Gynecologic
5
Other solid neoplasm
4
Genitourinary
3
Tumor-Agnostic
2
Other hematologic neoplasm
2
Myeloid
1
Head & Neck
1
Conditions
Neoplasms
2
Interventions
Gemcitabine
26
Paclitaxel
24
pembrolizumab
23
Carboplatin
22
Bevacizumab
18
Radiotherapy
16
Oxaliplatin
16
Erlotinib Hydrochloride
16
Nivolumab
15
Cisplatin
14
Capecitabine
14
Fluorouracil
13
Trastuzumab
12
Docetaxel
12
atezolizumab
11
Magnetic Resonance Spectroscopy
11
Leucovorin
11
Cyclophosphamide
11
Irinotecan
10
Ipilimumab
10
Vemurafenib
9
Everolimus
9
Cetuximab
9
cabozantinib
8
Radiosurgery
8
Afatinib
8
130-nm albumin-bound paclitaxel
8
trametinib
7
lenvatinib
7
durvalumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Temozolomide
×
Tumor-Agnostic
×
Clear all
NCT03899155
2026-05-27
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2
Recruiting
1,500 enrolled
NCT05999994
2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2
Recruiting
105 enrolled